Related Experiment Video
Updated: Aug 11, 2026

Mass Spectrometric Analysis of Glycosphingolipid Antigens
Published on: April 16, 2013
Miglustat: substrate reduction therapy for glycosphingolipid lysosomal storage disorders
1Charles Dent Metabolic Unit, The National Hospital for Neurology and Neurosurgery, London, UK. robin.lachmann@uclh.nhs.uk
Abstract:
Substrate reduction therapy offers a novel approach to the treatment of lysosomal storage disorders. By reducing the rate of macromolecule synthesis to a level where the residual degradative activity in the cell is sufficient to prevent substrate accumulation, it should be possible to reverse storage and storage-related pathologies. Miglustat is an N-alkylated imino sugar that acts against a number of enzymes involved in processing glycoconjugates, including the ceramide-specific glucosyltransferase, which catalyzes the initial committed step in glycosphingolipid synthesis. Miglustat could therefore be used for substrate reduction therapy in glycosphingolipid lysosomal storage disorders. This article addresses both the preclinical and clinical development of miglustat for treatment of type 1 Gaucher's disease, as well as related neuronopathic glycosphingolipidoses.
Related Concept Videos
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Lysosomal Hydrolases
Antiprotozoal Agents
Oligosaccharide Assembly
Multiple sugar molecules that may or may...
